Cerevast Therapeutics’ Ultrasonic Stroke Treatment Gains Momentum
Executive Summary
Cerevast Therapeutics is gaining momentum as the company raises new funds and advances enrollment in its pivotal Phase III clinical trial evaluating its Clotbust ER, an ultrasonic head-frame that delivers acoustic energy to the brain to enhance clot dissolution in acute ischemic stroke patients who receive intravenous tPA.
You may also be interested in...
Phase III Trial Of Cerevast’s Transcranial Ultrasound To Treat Stroke Misses Endpoint
The 90-day results of CLOTBUST ER, published in The Lancet, show sonothrombolysis to treat acute ischemic stroke is feasible and probably safe, but the trial did not show a clinical benefit of the therapy in conjunction with alteplase treatment.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.